Antibody
|
Month 3 IgG levels
|
Age (5–17 months)
|
Site (Manhiça)
|
Baseline IgG levels
|
WAZ
|
Vaccine (RTS,S)
|
---|
Antigen
|
OR
|
p
|
OR
|
p
|
OR
|
p
|
OR
|
p
|
OR
|
p
|
OR
|
p
|
---|
Group i antigens
|
MSP142 3D7
|
1.11 (0.7; 1.74)
|
0.65
| | |
0.18 (0.08; 0.39)
|
< 0.001
|
1.47 (0.96; 2.28)
|
0.08
| | | | |
MSP142 FVO
|
0.87 (0.57; 1.29)
|
0.48
|
0.5 (0.23; 1.04)
|
0.07
|
0.13 (0.05; 0.29)
|
< 0.001
|
1.47 (1.02;2.15)
|
0.04
|
0.78 (0.56; 1.08)
|
0.13
|
0.59 (0.28; 1.2)
|
0.15
|
EXP1
|
0.8 (0.47; 1.33)
|
0.39
| | |
0.19 (0.08; 0.43)
|
< 0.001
|
1.94 (1.24; 3.12)
|
0.005
|
0.75 (0.54; 1.05)
|
0.1
|
0.53 (0.25; 1.1)
|
0.09
|
AMA1 FVO
|
1.6 (1.15; 2.27)
|
0.006
| | |
0.13 (0.06; 0.25)
|
< 0.001
| | | | | | |
AMA1 3D7
|
0.98 (0.51; 1.83)
|
0.94
| | |
0.14 (0.07; 0.28)
|
< 0.001
|
1.54 (0.93; 2.67)
|
0.1
|
0.78 (0.56; 1.08)
|
0.14
|
0.56 (0.27; 1.15)
|
0.12
|
Group ii antigens
|
pTRAMP
|
1.01 (0.51; 2.03)
|
0.98
|
0.42 (0.2; 0.85)
|
0.02
|
0.12 (0.06; 0.25)
|
< 0.001
|
2.18 (1.16; 4.21)
|
0.02
| | |
0.54 (0.26; 1.11)
|
0.1
|
EBA175 R2(F2)
|
0.96 (0.56; 1.64)
|
0.89
|
0.49 (0.24; 0.98)
|
0.047
|
0.09 (0.04; 0.18)
|
< 0.001
| | | | | | |
PfRH1
|
1.58 (0.79; 3.19)
|
0.2
|
0.4 (0.18; 0.83)
|
0.02
|
0.11 (0.05; 0.23)
|
< 0.001
| | |
0.79 (0.56; 1.09)
|
0.15
| | |
MSP3 3D7
|
1.32 (0.77; 2.3)
|
0.32
|
0.51 (0.25; 1.02)
|
0.06
|
0.1 (0.05; 0.2)
|
< 0.001
| | | | | | |
Var2csa DBL3–4
|
1.03 (0.5;2.1)
|
0.94
|
0.5 (0.21; 1.13)
|
0.1
|
0.09 (0.04; 0.2)
|
< 0.001
| | | | | | |
p41
|
1.41 (0.64; 3.16)
|
0.4
|
0.46 (0.22; 0.94)
|
0.04
|
0.1 (0.05; 0.19)
|
< 0.001
| | | | | | |
MSP2 FL Dd2
|
0.89 (0.47; 1.61)
|
0.71
| | |
0.25 (0.11; 0.57)
|
0.001
|
2.15 (1.31; 3.67)
|
0.003
|
0.76 (0.54; 1.06)
|
0.11
|
0.52 (0.25; 1.07)
|
0.08
|
MSP2 FL CH150
|
1.02 (0.57; 1.83)
|
0.96
| | |
0.25 (0.11; 0.58)
|
0.001
|
2.05 (1.31; 3.29)
|
0.002
|
0.76 (0.54; 1.06)
|
0.11
|
0.44 (0.2; 0.92)
|
0.03
|
MSP1 Bl2 hybrid
|
1.11 (0.68; 1.83)
|
0.67
|
0.5 (0.24; 0.98)
|
0.049
|
0.09 (0.04; 0.19)
|
< 0.001
| | | | | | |
MSP3 3C
|
1.22 (0.74; 2.01)
|
0.43
|
0.41 (0.19; 0.84)
|
0.02
|
0.1 (0.05; 0.22)
|
< 0.001
|
1.67 (0.94; 2.99)
|
0.08
| | |
0.55 (0.27; 1.14)
|
0.11
|
PfRH2 b240
|
1.03 (0.49; 2.18)
|
0.94
|
0.49 (0.24; 0.98)
|
0.049
|
0.09 (0.04; 0.19)
|
< 0.001
| | | | | | |
LSA1
|
0.88 (0.51; 1.49)
|
0.64
|
0.5 (0.24; 0.99)
|
0.051
|
0.09 (0.04; 0.18)
|
< 0.001
| | | | | | |
MSP1 Bl2 PA17
|
0.96 (0.53; 1.7)
|
0.89
|
0.5 (0.24; 0.98)
|
0.048
|
0.09 (0.04; 0.18)
|
< 0.001
| | | | | | |
Var2csa DBL1–2
|
0.9 (0.37; 2.27)
|
0.82
| | |
0.14 (0.07; 0.29)
|
< 0.001
|
2.06 (1.01; 4.26)
|
0.047
| | |
0.57 (0.28; 1.16)
|
0.12
|
CyRPA
|
1.81 (0.76; 4.43)
|
0.18
|
0.4 (0.18; 0.82)
|
0.02
|
0.1 (0.04; 0.19)
|
< 0.001
| | |
0.79 (0.57; 1.09)
|
0.15
|
0.57 (0.28; 1.17)
|
0.13
|
CelTOS
|
1.55 (0.77; 3.13)
|
0.22
|
0.41 (0.19; 0.85)
|
0.02
|
0.1 (0.05; 0.2)
|
< 0.001
| | |
0.79 (0.57; 1.09)
|
0.16
|
0.58 (0.28; 1.18)
|
0.13
|
RH4.9
|
0.62 (0.3; 1.26)
|
0.19
|
0.53 (0.26; 1.05)
|
0.07
|
0.08 (0.04; 0.16)
|
< 0.001
| | | | | | |
Group iii antigens
|
DBL-α
|
1.35 (0.62; 2.91)
|
0.44
|
0.45 (0.21;0.92)
|
0.03
|
0.12 (0.05; 0.24)
|
< 0.001
|
1.9 (0.88; 4.22)
|
0.11
| | | | |
RH5
|
1.93 (0.98; 4.01)
|
0.07
|
0.38 (0.17; 0.79)
|
0.01
|
0.11 (0.05; 0.21)
|
< 0.001
| | |
0.78 (0.56; 1.08)
|
0.15
|
0.51 (0.24; 1.07)
|
0.08
|
SSP2 (TRAP)
|
0.52 (0.26; 0.98)
|
0.05
| | |
0.11 (0.05; 0.23)
|
< 0.001
|
2.29 (1.14; 4.8)
|
0.02
| | | | |
MSP1 Bl2 Mad20
|
0.61 (0.13; 2.7)
|
0.52
|
0.55 (0.26; 1.13)
|
0.11
|
0.14 (0.07; 0.3)
|
< 0.001
|
5.91 (1.5; 29.52)
|
0.02
|
0.79 (0.57; 1.09)
|
0.15
| | |
MSP6
|
1.19 (0.56; 2.61)
|
0.65
|
0.47 (0.21; 0.98)
|
0.05
|
0.14 (0.06; 0.3)
|
< 0.001
|
1.63 (0.89; 3.01)
|
0.12
|
0.78 (0.56; 1.07)
|
0.12
|
0.51 (0.23; 1.09)
|
0.08
|
RH2 (2030)
|
1.37 (0.72; 2.65)
|
0.35
|
0.51 (0.25; 1.01)
|
0.059
|
0.1 (0.04; 0.19)
|
< 0.001
| | | | |
0.55 (0.26; 1.16)
|
0.12
|
EBA175 R3–5
|
1.17 (0.71; 1.96)
|
0.54
|
0.45 (0.21; 0.91)
|
0.03
|
0.1 (0.05; 0.2)
|
< 0.001
| | |
0.79 (0.57; 1.09)
|
0.16
|
0.55 (0.25; 1.18)
|
0.13
|
MSP5
|
0.78 (0.48; 1.25)
|
0.3
|
0.49 (0.23; 1)
|
0.056
|
0.12 (0.06; 0.24)
|
< 0.001
|
2.06 (1.26; 3.45)
|
0.005
| | | | |
EBA140 R3–5
|
1.21 (0.69; 2.14)
|
0.5
|
0.47 (0.22; 0.94)
|
0.04
|
0.09 (0.04; 0.18)
|
< 0.001
| | | | |
0.54 (0.24; 1.19)
|
0.13
|
MSP1 Bl2 RO33
|
0.53 (0.3; 0.93)
|
0.03
|
0.53 (0.25; 1.07)
|
0.08
|
0.1 (0.04; 0.21)
|
< 0.001
|
1.64 (0.93; 3.03)
|
0.1
| | | | |
MSP1 Bl2 Well
|
0.55 (0.3; 0.99)
|
0.05
|
0.51 (0.23; 1.07)
|
0.08
|
0.1 (0.05; 0.2)
|
< 0.001
|
2.06 (0.95; 4.72)
|
0.08
| | | | |
MSP1 Bl2 3D7
|
0.63 (0.39; 1)
|
0.054
|
0.47 (0.22; 0.96)
|
0.042
|
0.08 (0.04; 0.17)
|
< 0.001
| | |
0.79 (0.56; 1.09)
|
0.16
| | |
RH4.2
|
0.85 (0.52; 1.38)
|
0.51
|
0.53 (0.25; 1.06)
|
0.08
|
0.09 (0.04; 0.18)
|
< 0.001
| | | | | | |
- Each line shows the multivariable logistic regression model’s results with IgG levels to each antigen (expressed as log10 of the median fluorescence intensity measured by quantitative suspension array technology) at month 3 as predictors and clinical malaria as outcome, adjusted by covariates. Columns show the odds ratio (OR) with 95% confidence intervals and p values (significant in italics) of the month 3 IgG levels and the covariables retained in the models for some antigens (in parenthesis the category that is compared to the reference). Variables that were not significant or did not improve the multivariable model are not shown. WAZ weight-for-age Z-score, FL full length, Bl2 block 2